Roles of glial cells in schizophrenia: Possible targets for therapeutic approaches

Neurobiology of Disease

Volumn 53, Issue , 2013, Pages 49-60

  Takahashi, Nagahide ^a   Sakurai, Takeshi ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Astrocyte; D serine; Glycogen; Kynurenic acid; Microglia; Myelination; Neuroinflammation; NG2 positive cells; Oligodendrocyte; Synapse

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DEXTRO SERINE; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLYCOGEN; HALOPERIDOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENIC ACID; LEUKEMIA INHIBITORY FACTOR; MINOCYCLINE; OLANZAPINE; PROTEOGLYCAN; QUETIAPINE; SCLEROPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE; CELL FUNCTION; CELL INTERACTION; CELL LINEAGE; CELL PROLIFERATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GLIA CELL; GLYCOGEN METABOLISM; HUMAN; MICROGLIA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MYELINATION; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NERVE NET; NEUROGLIA; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84875101622     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.11.001     Document Type: Review

References (173)

1. Abazyan B., Nomura J., Kannan G., Ishizuka K., Tamashiro K.L., Nucifora F., et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 2010, 68:1172-1181.
2. Aberg K., Saetre P., Jareborg N., Jazin E. Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7482-7487.
3. Aberg K., Saetre P., Lindholm E., Ekholm B., Pettersson U., Adolfsson R., et al. Human QKI, a new candidate gene for schizophrenia involved in myelination. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:84-90.
4. Allaman I., Belanger M., Magistretti P.J. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011, 34:76-87.
5. Amar S., Belmaker R.H., Agam G. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. Curr. Pharm. Des. 2011, 17:2264-2277.
6. Antony J.M. Grooming and growing with microglia. Sci. Signal. 2010, 3:jc8.
7. Aoyama N., Takahashi N., Saito S., Maeno N., Ishihara R., Ji X., et al. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav. 2006, 5:364-368.
8. Archer T. Neurodegeneration in schizophrenia. Expert Rev. Neurother. 2010, 10:1131-1141.
9. Arnold S.E., Franz B.R., Trojanowski J.Q., Moberg P.J., Gur R.E. Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathol. 1996, 91:269-277.
10. Attwell D., Buchan A.M., Charpak S., Lauritzen M., Macvicar B.A., Newman E.A. Glial and neuronal control of brain blood flow. Nature 2010, 468:232-243.
11. Barker A.J., Ullian E.M. Astrocytes and synaptic plasticity. Neuroscientist 2010, 16:40-50.
12. Barr C.E., Mednick S.A., Munk-Jorgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch. Gen. Psychiatry 1990, 47:869-874.
13. Barres B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60:430-440.
14. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
15. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 2011, 168:1303-1310.
16. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:42-48.
17. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front. Behav. Neurosci. 2009, 3:14.
18. Bongarzone E.R., Howard S.G., Schonmann V., Campagnoni A.T. Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. J. Neurosci. 1998, 18:5344-5353.
19. Budel S., Padukkavidana T., Liu B.P., Feng Z., Hu F., Johnson S., et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J. Neurosci. 2008, 28:13161-13172.
20. Buxbaum J.D., Georgieva L., Young J.J., Plescia C., Kajiwara Y., Jiang Y., et al. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Mol. Psychiatry 2008, 13:162-172.
21. Casanova M.F., Stevens J.R., Kleinman J.E. Astrocytosis in the molecular layer of the dentate gyrus: a study in Alzheimer's disease and schizophrenia. Psychiatry Res. 1990, 35:149-166.
22. Cohen-Cory S., Kidane A.H., Shirkey N.J., Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev. Neurobiol. 2010, 70:271-288.
23. Damadzic R., Bigelow L.B., Krimer L.S., Goldenson D.A., Saunders R.C., Kleinman J.E., et al. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res. Bull. 2001, 55:611-618.
24. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003, 60:443-456.
25. De Biase L.M., Nishiyama A., Bergles D.E. Excitability and synaptic communication within the oligodendrocyte lineage. J. Neurosci. 2010, 30:3600-3611.
26. de Jong S., van Eijk K.R., Zeegers D.W., Strengman E., Janson E., Veldink J.H., et al. Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes. Eur. J. Hum. Genet. 2012, 20:1004-1008.
27. De Keyser J., Mostert J.P., Koch M.W. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J. Neurol. Sci. 2008, 267:3-16.
28. Derecki N.C., Cronk J.C., Lu Z., Xu E., Abbott S.B., Guyenet P.G., et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
29. Dracheva S., Davis K.L., Chin B., Woo D.A., Schmeidler J., Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol. Dis. 2006, 21:531-540.
30. Edgar N., Sibille E. A putative functional role for oligodendrocytes in mood regulation. Transl. Psychiatry 2012, 2:e109.
31. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23:91-101.
32. Eroglu C., Barres B.A. Regulation of synaptic connectivity by glia. Nature 2010, 468:223-231.
33. Faissner A., Pyka M., Geissler M., Sobik T., Frischknecht R., Gundelfinger E.D., et al. Contributions of astrocytes to synapse formation and maturation - potential functions of the perisynaptic extracellular matrix. Brain Res. Rev. 2010, 63:26-38.
34. Falkai P., Honer W.G., David S., Bogerts B., Majtenyi C., Bayer T.A. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol. Appl. Neurobiol. 1999, 25:48-53.
35. Fatemi S.H., Laurence J.A., Araghi-Niknam M., Stary J.M., Schulz S.C., Lee S., et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr. Res. 2004, 69:317-323.
36. Ferraris D.V., Tsukamoto T. Recent advances in the discovery of d-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr. Pharm. Des. 2011, 17:103-111.
37. Fields R.D. Neuroscience. Change in the brain's white matter. Science 2010, 330:768-769.
38. Fillman, S.G., Cloonan, N., Catts, V.S., Miller, L.C., Wong, J., McCrossin, T., et al., in press. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry Electronic publication ahead of print.
39. Foster R., Kandanearatchi A., Beasley C., Williams B., Khan N., Fagerhol M.K., et al. Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process?. Eur. J. Neurosci. 2006, 24:3561-3566.
40. Friedman J.I., Vrijenhoek T., Markx S., Janssen I.M., van der Vliet W.A., Faas B.H., et al. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol. Psychiatry 2008, 13:261-266.
41. Fujii K., Maeda K., Hikida T., Mustafa A.K., Balkissoon R., Xia J., et al. Serine racemase binds to PICK1: potential relevance to schizophrenia. Mol. Psychiatry 2006, 11:150-157.
42. Funfschilling U., Supplie L.M., Mahad D., Boretius S., Saab A.S., Edgar J., et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012, 485:517-521.
43. Georgieva L., Moskvina V., Peirce T., Norton N., Bray N.J., Jones L., et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12469-12474.
44. Gomez-Galan, M., De Bundel, D., Van Eeckhaut, A., Smolders, I., Lindskog, M., in press. Dysfunctional astrocytic regulation of glutamate transmission in a rat model of depression. Mol. Psychiatry Electronic publication ahead of print.
45. Graeber M.B. Changing face of microglia. Science 2010, 330:783-788.
46. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4746-4751.
47. Hamilton N.B., Attwell D. Do astrocytes really exocytose neurotransmitters?. Nat. Rev. Neurosci. 2010, 11:227-238.
48. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1758-1759. (author reply 60).
49. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med. Chem. J. 2010, 4:10-19.
50. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
51. Hashimoto R., Straub R.E., Weickert C.S., Hyde T.M., Kleinman J.E., Weinberger D.R. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol. Psychiatry 2004, 9:299-307.
52. Hof P.R., Haroutunian V., Friedrich V.L., Byne W., Buitron C., Perl D.P., et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 2003, 53:1075-1085.
53. Hoistad M., Segal D., Takahashi N., Sakurai T., Buxbaum J.D., Hof P.R. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front. Neuroanat. 2009, 3:9.
54. Holtze M., Saetre P., Engberg G., Schwieler L., Werge T., Andreassen O.A., et al. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J. Psychiatry Neurosci. 2012, 37:53-57.
55. Hsiao E.Y., McBride S.W., Chow J., Mazmanian S.K., Patterson P.H. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:12776-12781.
56. Ibi D., Nagai T., Koike H., Kitahara Y., Mizoguchi H., Niwa M., et al. Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behav. Brain Res. 2010, 206:32-37.
57. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
58. Jones P.B., Rantakallio P., Hartikainen A.L., Isohanni M., Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am. J. Psychiatry 1998, 155:355-364.
59. Kantrowitz J.T., Malhotra A.K., Cornblatt B., Silipo G., Balla A., Suckow R.F., et al. High dose d-serine in the treatment of schizophrenia. Schizophr. Res. 2010, 121:125-130.
60. Kapoor R., Lim K.S., Cheng A., Garrick T., Kapoor V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 2006, 1106:205-210.
61. Kato T., Monji A., Hashioka S., Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 2007, 92:108-115.
62. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., Seki Y., et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem. 2008, 106:815-825.
63. Katsel P., Byne W., Roussos P., Tan W., Siever L., Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology 2011, 36:1171-1177.
64. Kellendonk C., Simpson E.H., Kandel E.R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 2009, 32:347-358.
65. Kimoto S., Okuda A., Toritsuka M., Yamauchi T., Makinodan M., Okuda H., et al. Olanzapine stimulates proliferation but inhibits differentiation in rat oligodendrocyte precursor cell cultures. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1950-1956.
66. Kirov G., Grozeva D., Norton N., Ivanov D., Mantripragada K.K., Holmans P., et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum. Mol. Genet. 2009, 18:1497-1503.
67. Kneeland, R.E., Fatemi, S.H., in press. Viral infection, inflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry Electronic publication ahead of print.
68. Kondziella D., Brenner E., Eyjolfsson E.M., Markinhuhta K.R., Carlsson M.L., Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 2006, 31:1880-1887.
69. Konopaske G.T., Dorph-Petersen K.A., Sweet R.A., Pierri J.N., Zhang W., Sampson A.R., et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol. Psychiatry 2008, 63:759-765.
70. Kucukdereli H., Allen N.J., Lee A.T., Feng A., Ozlu M.I., Conatser L.M., et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E440-E449.
71. Kuroda K., Yamada S., Tanaka M., Iizuka M., Yano H., Mori D., et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum. Mol. Genet. 2011, 20:4666-4683.
72. Kyriakopoulos M., Frangou S. Recent diffusion tensor imaging findings in early stages of schizophrenia. Curr. Opin. Psychiatry 2009, 22:168-176.
73. Kyriakopoulos M., Bargiotas T., Barker G.J., Frangou S. Diffusion tensor imaging in schizophrenia. Eur. Psychiatry 2008, 23:255-273.
74. Labrie V., Fukumura R., Rastogi A., Fick L.J., Wang W., Boutros P.C., et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum. Mol. Genet. 2009, 18:3227-3243.
75. Lavoie S., Allaman I., Petit J.M., Do K.Q., Magistretti P.J. Altered glycogen metabolism in cultured astrocytes from mice with chronic glutathione deficit; relevance for neuroenergetics in schizophrenia. PLoS One 2011, 6:e22875.
76. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
77. Li D., Feng G., He L. Case-control study of association between the functional candidate gene ERBB3 and schizophrenia in Caucasian population. World J. Biol. Psychiatry 2009, 10:595-598.
78. Lin C.Y., Sawa A., Jaaro-Peled H. Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models. Neurobiol. Dis. 2012, 45:48-56.
79. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am. J. Hum. Genet. 2001, 69:96-105.
80. Liu J., Casaccia P. Epigenetic regulation of oligodendrocyte identity. Trends Neurosci. 2010, 33:193-201.
81. Liu X., Qin W., He G., Yang Y., Chen Q., Zhou J., et al. A family-based association study of the MOG gene with schizophrenia in the Chinese population. Schizophr. Res. 2005, 73:275-280.
82. Ma, T.M., Abazyan, S., Abazyan, B., Nomura, J., Yang, C., Seshadri, S., et al., in press. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol. Psychiatry Electronic publication ahead of print.
83. Maeno N., Takahashi N., Saito S., Ji X., Ishihara R., Aoyama N., et al. Association of SOX10 with schizophrenia in the Japanese population. Psychiatr. Genet. 2007, 17:227-231.
84. Maezawa I., Calafiore M., Wulff H., Jin L.W. Does microglial dysfunction play a role in autism and Rett syndrome?. Neuron Glia Biol. 2012, 1-13.
85. Makinodan M., Yamauchi T., Tatsumi K., Okuda H., Takeda T., Kiuchi K., et al. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:978-985.
86. Makinodan M., Rosen K.M., Ito S., Corfas G. A critical period for social experience-dependent oligodendrocyte maturation and myelination. Science 2012, 337:1357-1360.
87. Marder S.R., Roth B., Sullivan P.F., Scolnick E.M., Nestler E.J., Geyer M.A., et al. Advancing drug discovery for schizophrenia. Ann. N. Y. Acad. Sci. 2011, 1236:30-43.
88. Martins-de-Souza D., Gattaz W.F., Schmitt A., Maccarrone G., Hunyadi-Gulyas E., Eberlin M.N., et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J. Psychiatr. Res. 2009, 43:978-986.
89. Martins-de-Souza D., Gattaz W.F., Schmitt A., Rewerts C., Marangoni S., Novello J.C., et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural Transm. 2009, 116:275-289.
90. Matute C., Melone M., Vallejo-Illarramendi A., Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005, 49:451-455.
91. Mednick S.A., Machon R.A., Huttunen M.O., Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 1988, 45:189-192.
92. Millar J.K., Christie S., Semple C.A., Porteous D.J. Chromosomal location and genomic structure of the human translin-associated factor X gene (TRAX; TSNAX) revealed by intergenic splicing to DISC1, a gene disrupted by a translocation segregating with schizophrenia. Genomics 2000, 67:69-77.
93. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
94. Miller, B.J., Culpepper, N., Rapaport, M.H., Buckley, P., in press. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry Electronic publication ahead of print.
95. Min R., Nevian T. Astrocyte signaling controls spike timing-dependent depression at neocortical synapses. Nat. Neurosci. 2012, 15:746-753.
96. Mistry, M., Gillis, J., Pavlidis, P., in press. Genome-wide expression profiling of schizophrenia using a large combined cohort. Mol. Psychiatry Electronic publication ahead of print.
97. Mitterauer B. Nonfunctional glial proteins in tripartite synapses: a pathophysiological model of schizophrenia. Neuroscientist 2005, 11:192-198.
98. Mitterauer B.J., Kofler-Westergren B. Possible effects of synaptic imbalances on oligodendrocyte-axonic interactions in schizophrenia: a hypothetical model. Front. Psychiatry 2011, 2:15.
99. Molina V., Papiol S., Sanz J., Rosa A., Arias B., Fatjo-Vilas M., et al. Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients. Neuroimage 2011, 56:45-51.
100. Monji, A., Kato, T.A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., et al., in press. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry Electronic publication ahead of print.
101. Morita Y., Ujike H., Tanaka Y., Otani K., Kishimoto M., Morio A., et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 2007, 61:1200-1203.
102. Muller N., Schwarz M.J. COX-2 inhibition in schizophrenia and major depression. Curr. Pharm. Des. 2008, 14:1452-1465.
103. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121:118-124.
104. Munn N.A. Microglia dysfunction in schizophrenia: an integrative theory. Med. Hypotheses 2000, 54:198-202.
105. Nave K.A. Myelination and support of axonal integrity by glia. Nature 2010, 468:244-252.
106. Nishiyama A., Komitova M., Suzuki R., Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat. Rev. Neurosci. 2009, 10:9-22.
107. Norton N., Moskvina V., Morris D.W., Bray N.J., Zammit S., Williams N.M., et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:96-101.
108. Pantazopoulos H., Woo T.U., Lim M.P., Lange N., Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch. Gen. Psychiatry 2010, 67:155-166.
109. Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011, 333:1456-1458.
110. Paul-Samojedny M., Owczarek A., Suchanek R., Kowalczyk M., Fila-Danilow A., Borkowska P., et al. Association study of interferon gamma (IFN-gamma) +874T/A gene polymorphism in patients with paranoid schizophrenia. J. Mol. Neurosci. 2011, 43:309-315.
111. Peirce T.R., Bray N.J., Williams N.M., Norton N., Moskvina V., Preece A., et al. Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch. Gen. Psychiatry 2006, 63:18-24.
112. Penas C., Verdu E., Asensio-Pinilla E., Guzman-Lenis M.S., Herrando-Grabulosa M., Navarro X., et al. Valproate reduces CHOP levels and preserves oligodendrocytes and axons after spinal cord injury. Neuroscience 2011, 178:33-44.
113. Perry V.H., Hume D.A., Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Neuroscience 1985, 15:313-326.
114. Pocivavsek A., Wu H.Q., Potter M.C., Elmer G.I., Pellicciari R., Schwarcz R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 2011, 36:2357-2367.
115. Powell S.B., Sejnowski T.J., Behrens M.M. Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology 2012, 62:1322-1331.
116. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9:684-697. (43).
117. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
118. Qin W., Gao J., Xing Q., Yang J., Qian X., Li X., et al. A family-based association study of PLP1 and schizophrenia. Neurosci. Lett. 2005, 375:207-210.
119. Qu M., Yue W., Tang F., Wang L., Han Y., Zhang D. Polymorphisms of transferrin gene are associated with schizophrenia in Chinese Han population. J. Psychiatr. Res. 2008, 42:877-883.
120. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 2002, 57:127-138.
121. Rapoport J.L., Addington A., Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us?. Curr. Psychiatry Rep. 2005, 7:81-82.
122. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10:434-449.
123. Rothermundt M., Falkai P., Ponath G., Abel S., Burkle H., Diedrich M., et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 2004, 9:897-899.
124. Rothermundt M., Ponath G., Glaser T., Hetzel G., Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 2004, 29:1004-1011.
125. Roussos P., Giakoumaki S.G., Adamaki E., Anastasios G., Nikos R.K., Bitsios P. The association of schizophrenia risk d-amino acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males. Neuropsychopharmacology 2011, 36:1677-1688.
126. Roussos P., Katsel P., Davis K.L., Bitsios P., Giakoumaki S.G., Jogia J., et al. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch. Gen. Psychiatry 2012, 69:7-15.
127. Rowitch D.H., Kriegstein A.R. Developmental genetics of vertebrate glial-cell specification. Nature 2010, 468:214-222.
128. Saijo K., Glass C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011, 11:775-787.
129. Schafer D.P., Lehrman E.K., Kautzman A.G., Koyama R., Mardinly A.R., Yamasaki R., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
130. Schlegelmilch T., Henke K., Peri F. Microglia in the developing brain: from immunity to behaviour. Curr. Opin. Neurobiol. 2011, 21:5-10.
131. Schmitz T., Chew L.J. Cytokines and myelination in the central nervous system. Sci. World J. 2008, 8:1119-1147.
132. Schnieder T.P., Dwork A.J. Searching for neuropathology: gliosis in schizophrenia. Biol. Psychiatry 2011, 69:134-139.
133. Schwarcz R., Hunter C.A. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?. Schizophr. Bull. 2007, 33:652-653.
134. Silberberg G., Darvasi A., Pinkas-Kramarski R., Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:142-148.
135. Smith J.A., Das A., Ray S.K., Banik N.L. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 2012, 87:10-20.
136. Stankoff B., Wang Y., Bottlaender M., Aigrot M.S., Dolle F., Wu C., et al. Imaging of CNS myelin by positron-emission tomography. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9304-9309.
137. Stankoff B., Freeman L., Aigrot M.S., Chardain A., Dolle F., Williams A., et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole. Ann. Neurol. 2011, 69:673-680.
138. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002, 71:877-892.
139. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
140. Steffek A.E., McCullumsmith R.E., Haroutunian V., Meador-Woodruff J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr. Res. 2008, 103:71-82.
141. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 2006, 112:305-316.
142. Stone T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci. 2000, 21:149-154.
143. Stroman P.W., Bosma R.L., Kornelsen J., Lawrence-Dewar J., Wheeler-Kingshott C., Cadotte D., et al. Advanced MR imaging techniques and characterization of residual anatomy. Clin. Neurol. Neurosurg. 2012, 114:460-470.
144. Sugai T., Kawamura M., Iritani S., Araki K., Makifuchi T., Imai C., et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann. N. Y. Acad. Sci. 2004, 1025:84-91.
145. Suzuki A., Stern S.A., Bozdagi O., Huntley G.W., Walker R.H., Magistretti P.J., et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011, 144:810-823.
146. Takahashi N., Sakurai T., Davis K.L., Buxbaum J.D. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog. Neurobiol. 2011, 93:13-24.
147. Tanahashi S., Yamamura S., Nakagawa M., Motomura E., Okada M. Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes. Br. J. Pharmacol. 2012, 165:1543-1555.
148. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
149. Togo T., Akiyama H., Kondo H., Ikeda K., Kato M., Iseki E., et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 2000, 885:117-121.
150. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33:729-736.
151. Tosic M., Otto J., Barral S., Bovet P., Deppen P., Gheorghita F., et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am. J. Hum. Genet. 2006, 79:586-592.
152. Tsai H.H., Li H., Fuentealba L.C., Molofsky A.V., Taveira-Marques R., Zhuang H., et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science 2012, 337:358-362.
153. Uranova N.A., Casanova M.F., DeVaughn N.M., Orlovskaya D.D., Denisov D.V. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr. Res. 1996, 22:81-83.
154. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
155. Uranova N.A., Vostrikov V.M., Vikhreva O.V., Zimina I.S., Kolomeets N.S., Orlovskaya D.D. The role of oligodendrocyte pathology in schizophrenia. Int. J. Neuropsychopharmacol. 2007, 10:537-545.
156. Vallejo-Illarramendi A., Torres-Ramos M., Melone M., Conti F., Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 2005, 50:276-279.
157. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64:820-822.
158. Verrall L., Walker M., Rawlings N., Benzel I., Kew J.N., Harrison P.J., et al. d-amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26:1657-1669.
159. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
160. Wan C., Yang Y., Feng G., Gu N., Liu H., Zhu S., et al. Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neurosci. Lett. 2005, 388:126-131.
161. Wang H., Xu H., Niu J., Mei F., Li X., Kong J., et al. Haloperidol activates quiescent oligodendroglia precursor cells in the adult mouse brain. Schizophr. Res. 2010, 119:164-174.
162. Watanabe A., Toyota T., Owada Y., Hayashi T., Iwayama Y., Matsumata M., et al. Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype. PLoS Biol. 2007, 5:e297.
163. Webster M.J., Knable M.B., Johnston-Wilson N., Nagata K., Inagaki M., Yolken R.H. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav. Immun. 2001, 15:388-400.
164. Webster M.J., O'Grady J., Kleinman J.E., Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005, 133:453-461.
165. Weigelt K., Carvalho L.A., Drexhage R.C., Wijkhuijs A., de Wit H., van Beveren N.J., et al. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav. Immun. 2011, 25:1162-1169.
166. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
167. Weis S., Llenos I.C., Dulay J.R., Verma N., Sabunciyan S., Yolken R.H. Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J. Neural Transm. 2007, 114:261-271.
168. Wonodi I., Stine O.C., Sathyasaikumar K.V., Roberts R.C., Mitchell B.D., Hong L.E., et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 2011, 68:665-674.
169. Xiao L., Xu H., Zhang Y., Wei Z., He J., Jiang W., et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 2008, 13:697-708.
170. Yang Y.F., Qin W., Shugart Y.Y., He G., Liu X.M., Zhou J., et al. Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophr. Res. 2005, 75:11-19.
171. Ye F., Chen Y., Hoang T., Montgomery R.L., Zhao X.H., Bu H., et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat. Neurosci. 2009, 12:829-838.
172. Zhang Y., Barres B.A. Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr. Opin. Neurobiol. 2010, 20:588-594.
173. Zhang Y., Xu H., Jiang W., Xiao L., Yan B., He J., et al. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res. 2008, 106:182-191.